Figure 1.
Distribution of spinal cord affected segments in neuromyelitis optica patients (n = 23).
Table 1.
Demographic and clinical features of neuromyelitis optica patients.
Table 2.
Comparison of clinical features between neuromyelitis optica patients with normal and abnormal motor evoked potentials.
Table 3.
Comparison of clinical features between neuromyelitis optica patients with normal and abnormal somatosensory evoked potentials.
Figure 2.
Scatter plots showing latencies of motor evoked potentials and somatosensory evoked potentials of NMO patients.
A. CxL in upper limbs; B, upper limb motor CCT; C, CxL in lower limbs; D, lower limb motor CCT; E, N20; F, upper limb sensory CCT; G, P40; H, lower limb sensory CCT. Black dots indicate patients with a relapse. Note in G (P40) and H (lower limb sensory CCT), among 17 patients with abnormal evoked potentials (dots above the dashed lines) 8 patients (47.1%) had a relapse within 6 months after the index event.
Table 4.
Comparison of changes of EDSS scores and frequencies of relapses within 6 months between neuromyelitis optica patients with normal and abnormal motor evoked potentials.
Table 5.
Comparison of changes of EDSS scores and frequencies of relapses within 6 months between Kurtzke Expanded Disability Status Scale patients with normal and abnormal somatosensory evoked potentials.